Diagnosis and treatment of metastatic melanoma of unknown primary
Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the di...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
M A Krylovetskaya [verfasserIn] I G Komarov [verfasserIn] D A Karseladze [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Современная онкология - IP Habib O.N., 2019, 20(2018), 3, Seite 30-34 |
|---|---|
| Übergeordnetes Werk: |
volume:20 ; year:2018 ; number:3 ; pages:30-34 |
| Links: |
|---|
| Katalog-ID: |
DOAJ010186530 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ010186530 | ||
| 003 | DE-627 | ||
| 005 | 20230310024002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2018 xx |||||o 00| ||rus c | ||
| 035 | |a (DE-627)DOAJ010186530 | ||
| 035 | |a (DE-599)DOAJcf17873d87da499f97f196d369d1fd25 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a M A Krylovetskaya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and treatment of metastatic melanoma of unknown primary |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. | ||
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a metastatic melanoma of unknown primary | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a survival | |
| 650 | 4 | |a immunohistochemical study | |
| 650 | 4 | |a combined treatment | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a I G Komarov |e verfasserin |4 aut | |
| 700 | 0 | |a D A Karseladze |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Современная онкология |d IP Habib O.N., 2019 |g 20(2018), 3, Seite 30-34 |w (DE-627)1760605514 |x 18151442 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2018 |g number:3 |g pages:30-34 |
| 856 | 4 | 0 | |u https://doaj.org/article/cf17873d87da499f97f196d369d1fd25 |z kostenfrei |
| 856 | 4 | 0 | |u https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1815-1434 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1815-1442 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2018 |e 3 |h 30-34 | ||
| author_variant |
m a k mak i g k igk d a k dak |
|---|---|
| matchkey_str |
article:18151442:2018----::igoiadramnomtsaimlnmo |
| hierarchy_sort_str |
2018 |
| callnumber-subject-code |
RC |
| publishDate |
2018 |
| allfields |
(DE-627)DOAJ010186530 (DE-599)DOAJcf17873d87da499f97f196d369d1fd25 DE-627 ger DE-627 rakwb rus RC254-282 M A Krylovetskaya verfasserin aut Diagnosis and treatment of metastatic melanoma of unknown primary 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. melanoma metastatic melanoma of unknown primary prognosis survival immunohistochemical study combined treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens I G Komarov verfasserin aut D A Karseladze verfasserin aut In Современная онкология IP Habib O.N., 2019 20(2018), 3, Seite 30-34 (DE-627)1760605514 18151442 nnns volume:20 year:2018 number:3 pages:30-34 https://doaj.org/article/cf17873d87da499f97f196d369d1fd25 kostenfrei https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2018 3 30-34 |
| spelling |
(DE-627)DOAJ010186530 (DE-599)DOAJcf17873d87da499f97f196d369d1fd25 DE-627 ger DE-627 rakwb rus RC254-282 M A Krylovetskaya verfasserin aut Diagnosis and treatment of metastatic melanoma of unknown primary 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. melanoma metastatic melanoma of unknown primary prognosis survival immunohistochemical study combined treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens I G Komarov verfasserin aut D A Karseladze verfasserin aut In Современная онкология IP Habib O.N., 2019 20(2018), 3, Seite 30-34 (DE-627)1760605514 18151442 nnns volume:20 year:2018 number:3 pages:30-34 https://doaj.org/article/cf17873d87da499f97f196d369d1fd25 kostenfrei https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2018 3 30-34 |
| allfields_unstemmed |
(DE-627)DOAJ010186530 (DE-599)DOAJcf17873d87da499f97f196d369d1fd25 DE-627 ger DE-627 rakwb rus RC254-282 M A Krylovetskaya verfasserin aut Diagnosis and treatment of metastatic melanoma of unknown primary 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. melanoma metastatic melanoma of unknown primary prognosis survival immunohistochemical study combined treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens I G Komarov verfasserin aut D A Karseladze verfasserin aut In Современная онкология IP Habib O.N., 2019 20(2018), 3, Seite 30-34 (DE-627)1760605514 18151442 nnns volume:20 year:2018 number:3 pages:30-34 https://doaj.org/article/cf17873d87da499f97f196d369d1fd25 kostenfrei https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2018 3 30-34 |
| allfieldsGer |
(DE-627)DOAJ010186530 (DE-599)DOAJcf17873d87da499f97f196d369d1fd25 DE-627 ger DE-627 rakwb rus RC254-282 M A Krylovetskaya verfasserin aut Diagnosis and treatment of metastatic melanoma of unknown primary 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. melanoma metastatic melanoma of unknown primary prognosis survival immunohistochemical study combined treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens I G Komarov verfasserin aut D A Karseladze verfasserin aut In Современная онкология IP Habib O.N., 2019 20(2018), 3, Seite 30-34 (DE-627)1760605514 18151442 nnns volume:20 year:2018 number:3 pages:30-34 https://doaj.org/article/cf17873d87da499f97f196d369d1fd25 kostenfrei https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2018 3 30-34 |
| allfieldsSound |
(DE-627)DOAJ010186530 (DE-599)DOAJcf17873d87da499f97f196d369d1fd25 DE-627 ger DE-627 rakwb rus RC254-282 M A Krylovetskaya verfasserin aut Diagnosis and treatment of metastatic melanoma of unknown primary 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. melanoma metastatic melanoma of unknown primary prognosis survival immunohistochemical study combined treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens I G Komarov verfasserin aut D A Karseladze verfasserin aut In Современная онкология IP Habib O.N., 2019 20(2018), 3, Seite 30-34 (DE-627)1760605514 18151442 nnns volume:20 year:2018 number:3 pages:30-34 https://doaj.org/article/cf17873d87da499f97f196d369d1fd25 kostenfrei https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 20 2018 3 30-34 |
| language |
Russian |
| source |
In Современная онкология 20(2018), 3, Seite 30-34 volume:20 year:2018 number:3 pages:30-34 |
| sourceStr |
In Современная онкология 20(2018), 3, Seite 30-34 volume:20 year:2018 number:3 pages:30-34 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
melanoma metastatic melanoma of unknown primary prognosis survival immunohistochemical study combined treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Современная онкология |
| authorswithroles_txt_mv |
M A Krylovetskaya @@aut@@ I G Komarov @@aut@@ D A Karseladze @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
1760605514 |
| id |
DOAJ010186530 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010186530</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310024002.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010186530</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcf17873d87da499f97f196d369d1fd25</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M A Krylovetskaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Diagnosis and treatment of metastatic melanoma of unknown primary</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">melanoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastatic melanoma of unknown primary</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunohistochemical study</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">combined treatment</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I G Komarov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D A Karseladze</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Современная онкология</subfield><subfield code="d">IP Habib O.N., 2019</subfield><subfield code="g">20(2018), 3, Seite 30-34</subfield><subfield code="w">(DE-627)1760605514</subfield><subfield code="x">18151442</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:30-34</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cf17873d87da499f97f196d369d1fd25</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1815-1434</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1815-1442</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="h">30-34</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
M A Krylovetskaya |
| spellingShingle |
M A Krylovetskaya misc RC254-282 misc melanoma misc metastatic melanoma of unknown primary misc prognosis misc survival misc immunohistochemical study misc combined treatment misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Diagnosis and treatment of metastatic melanoma of unknown primary |
| authorStr |
M A Krylovetskaya |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760605514 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
18151442 |
| topic_title |
RC254-282 Diagnosis and treatment of metastatic melanoma of unknown primary melanoma metastatic melanoma of unknown primary prognosis survival immunohistochemical study combined treatment |
| topic |
misc RC254-282 misc melanoma misc metastatic melanoma of unknown primary misc prognosis misc survival misc immunohistochemical study misc combined treatment misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc melanoma misc metastatic melanoma of unknown primary misc prognosis misc survival misc immunohistochemical study misc combined treatment misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc melanoma misc metastatic melanoma of unknown primary misc prognosis misc survival misc immunohistochemical study misc combined treatment misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Современная онкология |
| hierarchy_parent_id |
1760605514 |
| hierarchy_top_title |
Современная онкология |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760605514 |
| title |
Diagnosis and treatment of metastatic melanoma of unknown primary |
| ctrlnum |
(DE-627)DOAJ010186530 (DE-599)DOAJcf17873d87da499f97f196d369d1fd25 |
| title_full |
Diagnosis and treatment of metastatic melanoma of unknown primary |
| author_sort |
M A Krylovetskaya |
| journal |
Современная онкология |
| journalStr |
Современная онкология |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
30 |
| author_browse |
M A Krylovetskaya I G Komarov D A Karseladze |
| container_volume |
20 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
M A Krylovetskaya |
| author2-role |
verfasserin |
| title_sort |
diagnosis and treatment of metastatic melanoma of unknown primary |
| callnumber |
RC254-282 |
| title_auth |
Diagnosis and treatment of metastatic melanoma of unknown primary |
| abstract |
Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. |
| abstractGer |
Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. |
| abstract_unstemmed |
Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
3 |
| title_short |
Diagnosis and treatment of metastatic melanoma of unknown primary |
| url |
https://doaj.org/article/cf17873d87da499f97f196d369d1fd25 https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf https://doaj.org/toc/1815-1434 https://doaj.org/toc/1815-1442 |
| remote_bool |
true |
| author2 |
I G Komarov D A Karseladze |
| author2Str |
I G Komarov D A Karseladze |
| ppnlink |
1760605514 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T13:29:13.781Z |
| _version_ |
1803564722456363008 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010186530</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310024002.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010186530</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcf17873d87da499f97f196d369d1fd25</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M A Krylovetskaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Diagnosis and treatment of metastatic melanoma of unknown primary</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Melanoma is a malignant tumor that originates in melanocytes. Melanoma is characterized by rapid and early development of metastatic disease. Most often, metastases develop in regional lymph nodes. Metastases of melanoma can be the first signs of advanced process and the only manifestation of the disease. Patients with metastatic melanoma of unknown primary site represent approximately 1 to 8% of all cases of melanoma and up to 12.6% of all cases of metastatic melanoma of unknown primary site. The understanding of clinical course of metastatic melanoma of unknown primary is necessary to determine disease prognosis. This article shows the analysis of issues devoted to the description of the clinical manifestations of the disease and the characteristics of the clinical course, depending on the localization of the tumor.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">melanoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastatic melanoma of unknown primary</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunohistochemical study</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">combined treatment</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I G Komarov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D A Karseladze</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Современная онкология</subfield><subfield code="d">IP Habib O.N., 2019</subfield><subfield code="g">20(2018), 3, Seite 30-34</subfield><subfield code="w">(DE-627)1760605514</subfield><subfield code="x">18151442</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:30-34</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cf17873d87da499f97f196d369d1fd25</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://modernonco.orscience.ru/1815-1434/article/viewFile/29564/pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1815-1434</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1815-1442</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="h">30-34</subfield></datafield></record></collection>
|
| score |
7.400319 |